Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 65,359 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 65,359 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $0.47, for a total value of $30,718.73. Following the completion of the sale, the director now owns 4,012,320 shares in the company, valued at approximately $1,885,790.40. The trade was a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Stock Down 9.3 %

Shares of IVVD stock opened at $0.44 on Thursday. The stock has a market cap of $53.18 million, a PE ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 52-week low of $0.44 and a 52-week high of $5.20. The business has a 50-day simple moving average of $0.80 and a 200-day simple moving average of $1.03.

Analysts Set New Price Targets

IVVD has been the topic of several recent research reports. Morgan Stanley dropped their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, HC Wainwright cut their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $7.89.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently made changes to their positions in IVVD. Duquesne Family Office LLC acquired a new stake in Invivyd during the second quarter valued at $629,000. Acadian Asset Management LLC increased its stake in shares of Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after purchasing an additional 474,301 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter worth about $86,000. Cubist Systematic Strategies LLC grew its holdings in Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after buying an additional 25,201 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.